While its merger with AbbVie is being finalised, Allergan has partnered with clinical-stage biotech company, Exicure, to develop treatments for hair loss disorders utilising Exicure’s proprietary SNA™ (spherical nucleic acid) technology. The deal, worth up to US$820 M, will focus on androgenetic alopecia for which Allergan has prior experience with setipiprant that it gained from the US$2.1 B acquisition of Kythera Biopharmaceuticals in 2015.